德意志银行-美国市场研究-athenex:de- risking drug development-20170710-deutsche bank.pdfVIP

  • 4
  • 0
  • 约18.93万字
  • 约 38页
  • 2019-11-08 发布于广东
  • 举报

德意志银行-美国市场研究-athenex:de- risking drug development-20170710-deutsche bank.pdf

Deutsche Bank Markets Research Rating Company Date Buy Athenex 10 July 2017 Initiation of Coverage North America United States Reuters Bloomberg Exchange Ticker Price at 7 Jul 2017 (USD) 18.42 Health Care ATNX.OQ ATNX US NAS ATNX Price target - 12mth (USD) 20.00 Biotechnology 52-week range (USD) 18.42 - 12.56 HANG SENG INDEX 25,341 De-risking drug development Jack Hu, PhD Linc Yiu Research Analyst Research Associate (+852 ) 2203 6208 (+852 ) 2203 6248 Differentiated assets drive value creation jack.hu@ linc.yiu@ Athenex has two oncology assets in clinical stages: an oral chemotherapeutic platform and a Src kinase inhibitor pipeline. The primary value driver, Oraxol, Andrew Peters which comes from the chemo platform, is likely to offer

您可能关注的文档

文档评论(0)

1亿VIP精品文档

相关文档